AstraZeneca’s hopes of positioning its PD-L1 inhibitor Imfinzi as a post-surgery therapy for people with earlier-stage lung cancer have taken a knock, although it performed well in a bladder ...

It remains to be seen if the data with Keytruda will be strong enough to supplant Imfinzi (durvalumab), which was approved for BTC by the FDA last year on the back of data from the TOPAZ-1 trial ...

One option is an immunotherapy medicine called Imfinzi (durvalumab). Immunotherapy medicines work by helping your immune system find and attack cancer cells. The FDA approved Imfinzi in 2017.

Now, a newer option is available: an immunotherapy medicine called Imfinzi (durvalumab). Immunotherapy medicines work by helping your immune system find and attack cancer cells. The FDA approved ...

Astrazeneca's lung cancer drug, Imfinzi, has received approval for use in the US both pre and post-surgery. This comes just days after the pharmaceutical giant's market value reached £200bn for ...

AstraZeneca has a diverse product portfolio and a global footprint. Its key drugs like Lynparza, Tagrisso, Imfinzi, Fasenra, ...